非酒精性脂肪性肝病无创评估的应用与前景

摘要/Abstract

摘要： 非酒精性脂肪性肝病患者的肝纤维化和脂肪变程度与其预后密切相关。肝穿病理可以作为非酒精性脂肪性肝病患者肝纤维化和脂肪变评价的金标准,但具有一定局限性。因此,近年来涌现了较多无创检测手段,并在临床广泛应用。本文总结了不同的无创检测方法在评估非酒精性脂肪性肝病患者肝纤维化和脂肪变程度,及其对疾病预后的预测价值。

关键词: 非酒精性脂肪性肝病, 肝纤维化, 脂肪变性, 无创评估

孙成林, 孙亚朦, 陈姝延, 尤红. 非酒精性脂肪性肝病无创评估的应用与前景[J]. 肝脏, 2023, 28(8): 889-891.

[1] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022, 7(9):851-861.
[2] Zhou F, Zhou J, Wang W, et al. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology, 2019, 70(4):1119-1133.
[3] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair:; EASL Governing Board representative:; Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol, 2021, 75(3):659-689.
[4] Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2021, 161(5):1657-1669.
[5] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, 77(5):1797-1835.
[6] Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol, 2023, 79(2):277-286.
[7] Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71(5):1006-1019.
[8] Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology, 2017, 66:1486-1501.
[9] NMPA.非酒精性脂肪性肝炎治疗药物临床试验技术指导原则(试行). 2019年12月
[10] Loomba R, Cui J, Wolfson T, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol, 2016, 111:986-894.
[11] Kleiner DE, Brunt EM, Wilson LA, et al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open, 2019, 2(10):e1912565.
[12] Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol, 2020, 5:362-373.
[13] Noureddin M, Truong E, Gornbein JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol, 2022, 76(4):781-787.
[14] Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology, 2011, 54(3):1082-1090.
[15] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).临床肝胆病杂志, 2018, 34(05):947-957.
[16] Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol, 2017, 66:1022–1030.
[17] Gu J, Liu S, Du S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol, 2019, 29(7):3564-3573.
[18] Rinella ME, Dufour JF, Anstee QM, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol, 2022, 76(3):536-548.
[19] Balkhed W, Åberg FO, Nasr P, et al. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study. Liver Int, 2022, 42(7):1545-1556.
[20] Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol, 2019, 70(1):133-141.
[21] Ajmera V, Kim BK, Yang K, et al. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology, 2022, 163(4):1079-1089.e5.
[22] Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology, 2013, 57(4):1357-1365.
[23] Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2022;75(5):1235-1246.

非酒精性脂肪性肝病无创评估的应用与前景

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	管炬博, 范建高. 非酒精性脂肪性肝病患者心血管疾病风险的研究进展[J]. 肝脏, 2023, 28(8): 892-893.
[2]	陈勇良, 赵辉, 王晓静, 李秋雨, 潘丽, 李振燕. 肝静脉彩色多普勒血流频谱在肝纤维化分期中的临床价值[J]. 肝脏, 2023, 28(8): 907-911.
[3]	郑慕阳, 胡海, 范显文. 急性表现的自身免疫性肝炎的临床和病理特征分析[J]. 肝脏, 2023, 28(8): 953-956.
[4]	陈黎霞, 沈丽磊, 郑毅. 红细胞分布宽度-血小板比值评估自身免疫性肝炎患者肝纤维化严重程度的回顾性研究[J]. 肝脏, 2023, 28(8): 957-960.
[5]	裴宇梅, 张智慧, 连丽丽. 血清铁蛋白水平与初治自身免疫性肝炎晚期肝纤维化的关系[J]. 肝脏, 2023, 28(8): 961-964.
[6]	张明明, 汪艳. 线粒体应激参与慢性乙型肝炎肝损伤的机制研究[J]. 肝脏, 2023, 28(7): 743-745.
[7]	管炬博, 范建高. 非酒精性脂肪性肝病发病的脂肪组织功能障碍学说[J]. 肝脏, 2023, 28(7): 746-748.
[8]	邓朝华, 施军平. 孟德尔随机化分析在非酒精性脂肪性肝病危险因素研究中的应用[J]. 肝脏, 2023, 28(7): 749-750.
[9]	张思敏, 杜晟楠, 袁乙富, 何诗嘉, 曹勤, 蒋元烨. 瘦型非酒精性脂肪性肝病的临床特征及血清脂质组学研究[J]. 肝脏, 2023, 28(7): 799-805.
[10]	赵心怡, 孙杰, 徐炜新. 血清Maresin-1水平变化对非酒精性脂肪性肝病的影响[J]. 肝脏, 2023, 28(7): 806-809.
[11]	李洪林, 邓全敏. 肥胖儿童非酒精性脂肪性肝病血清25(OH)D水平变化及临床意义[J]. 肝脏, 2023, 28(7): 810-813.
[12]	王媛媛, 李潇萌, 丁秀婷. 幽门螺旋杆菌与非酒精性脂肪性肝病的相关性及根除Hp对代谢指标的影响[J]. 肝脏, 2023, 28(7): 814-817.
[13]	栗雯霏, 张捷, 栗建辉. 影像技术对非酒精性脂肪肝的评价[J]. 肝脏, 2023, 28(7): 875-880.
[14]	曾伟兰, 汪艳. 内质网应激与非酒精性脂肪性肝病肝损伤[J]. 肝脏, 2023, 28(6): 633-636.
[15]	陈倩倩, 杨玥, 倪文婧, 芮法娟, 施军平, 李婕. 非酒精性脂肪性肝病相关肝细胞癌的防治策略研究进展[J]. 肝脏, 2023, 28(6): 639-643.